Cotazym market seen growing through 2030 on digestive care demand

The Business Research Company says the Cotazym market is being lifted by rising gastrointestinal disease, more diagnoses of pancreatic insufficiency and broader use of enzyme replacement therapy. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region through the forecast period.

Why it matters: - Cotazym demand is tied to a wider rise in digestive disease, pancreatic insufficiency and chronic care needs. - Growth in enzyme replacement therapy and specialty gastroenterology care could expand use through 2030. - The market matters beyond treatment settings because Cotazym also supports biologics and biotechnology applications.

What happened: - The Business Research Company released a Cotazym market segmentation analysis on Nov. 2, 2026. - The report says the Cotazym market has grown on the back of stronger clinical acceptance of enzyme replacement therapies. - North America led the Cotazym market by size in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also published a free sample report and a full report online: Download the sample report and View the full report.

The details: - Cotazym is a pancreatic enzyme preparation made with amylase, lipase and protease. - The enzymes break down carbohydrates, fats and proteins to support digestion and nutrient absorption. - Cotazym is used for pancreatic insufficiency, when the pancreas does not make enough enzymes to digest food properly. - Historical growth was driven by higher cystic fibrosis rates, greater awareness of pancreatic disorders, hospital-led management of digestive diseases and improved diagnostics. - Future growth is expected to be supported by rising chronic pancreatitis, an aging population, better access to digestive care, a stronger focus on nutrition optimization and more specialty gastroenterology clinics. - Key trends include rising demand for pancreatic enzyme replacement therapy, more diagnoses of pancreatic insufficiency, longer-term enzyme supplementation and improved enzyme formulations that support nutrient absorption. - Rising gastrointestinal disease rates are a major market driver. - High processed-food consumption and obesity are contributing to digestive disorders affecting the stomach, intestines, liver and pancreas. - Cotazym helps address enzyme deficiencies, improve nutrient absorption and ease digestive discomfort. - In September 2023, the US National Institutes of Health said Canada had about 825 inflammatory bowel disease cases per 100,000 people, totaling more than 320,000 cases. - The NIH projected that number could rise by 2.44% annually to 470,000 cases by 2035. - Growing demand for biologics is another driver. - The report says Cotazym can improve enzymatic reactions, process efficiency and yields in biotechnology applications. - As of 2024, the US Food and Drug Administration had approved 76 biosimilars, compared with more than 30,000 approved generic drugs. - Rising rare genetic disorder diagnoses are also supporting usage. - Cotazym helps patients with cystic fibrosis and other genetic disorders by replacing pancreatic enzymes needed for digestion. - The UK-based Cystic Fibrosis Trust said the number of people living with cystic fibrosis in the UK rose from 11,148 in 2022 to 11,318 in 2023. - The 2026 report adds market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based dashboards, market hotspot infographics and updated graphics and tables.

Between the lines: - The report points to two separate demand pools: patient treatment and industrial biotechnology. - North America’s lead suggests the market is already mature in developed healthcare systems, while Asia-Pacific growth signals room for faster expansion where diagnosis and access are improving. - More specialty clinics and stronger diagnostic tools are likely to make pancreatic insufficiency visible earlier, which can widen the addressable market.

What's next: - The market outlook now depends on whether rising digestive disease rates, better diagnosis and broader access to enzyme therapy continue to outpace pricing and reimbursement pressure. - Regional growth in Asia-Pacific will be a key test of how quickly Cotazym adoption spreads beyond established North American demand. - Continued biosimilar growth and biotechnology use could add a second layer of demand if industrial applications keep expanding.

The bottom line: - Cotazym’s growth story is being driven by more patients who need digestive support and by broader use in biologics-linked manufacturing.